Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FXTE6
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,483
Award facts
- Contract value 100% obligated
- $12,483.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,483.06 delivery order to AmerisourceBergen Drug Corp on January 8, 2026, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, non-set-aside contract is structured as a firm fixed-price delivery order with an ultimate completion date of January 9, 2026, and will be performed at the awardee's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, representing a critical pharmaceutical supply for military healthcare systems.
This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp operates as a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), a major pharmaceutical distributor and healthcare solutions provider. The company's extensive federal contract portfolio demonstrates its established capability to efficiently fulfill government requirements for specialty medications, brand-name and generic drugs, vaccines, and other critical medical commodities across multiple therapeutic domains in support of military treatment facilities and veterans' healthcare programs.
Quick answers
Who was awarded contract SPE2DR26FXTE6?
SPE2DR26FXTE6 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FXTE6 worth?
The government has obligated $12,483 on SPE2DR26FXTE6.
Is contract SPE2DR26FXTE6 an order under another contract?
Yes. SPE2DR26FXTE6 is a delivery order under SPE2DR25D3004, an indefinite delivery contract.
Was contract SPE2DR26FXTE6 competed?
The extent of competition for SPE2DR26FXTE6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award